| Zacks Company Profile for Regeneron Pharmaceuticals, Inc. (REGN : NSDQ) |
|
|
| |
| • Company Description |
| Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
Number of Employees: 15,106 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $771.87 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 750,598 shares |
| Shares Outstanding: 105.10 (millions) |
| Market Capitalization: $81,123.12 (millions) |
| Beta: 0.39 |
| 52 Week High: $792.77 |
| 52 Week Low: $476.49 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
6.79% |
6.97% |
| 12 Week |
35.44% |
33.26% |
| Year To Date |
0.00% |
0.00% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Leonard S. Schleifer - Chief Executive Officer; Board co-Chair and Presid
George D. Yancopoulos - Board co-Chair; President and Chief Scientific Off
Christopher Fenimore - Executive Vice President; Finance and Chief Financ
Jason Pitofsky - Vice President; Controller
Bonnie L. Bassler - Director
|
|
Peer Information
Regeneron Pharmaceuticals, Inc. (CORR.)
Regeneron Pharmaceuticals, Inc. (RSPI)
Regeneron Pharmaceuticals, Inc. (CGXP)
Regeneron Pharmaceuticals, Inc. (BGEN)
Regeneron Pharmaceuticals, Inc. (GTBP)
Regeneron Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 75886F107
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/03/26
|
|
Share - Related Items
Shares Outstanding: 105.10
Most Recent Split Date: (:1)
Beta: 0.39
Market Capitalization: $81,123.12 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.46% |
| Current Fiscal Quarter EPS Consensus Estimate: $7.49 |
Indicated Annual Dividend: $3.52 |
| Current Fiscal Year EPS Consensus Estimate: $33.50 |
Payout Ratio: 0.10 |
| Number of Estimates in the Fiscal Year Consensus: 8.00 |
Change In Payout Ratio: 0.09 |
| Estmated Long-Term EPS Growth Rate: 10.01% |
Last Dividend Paid: 11/20/2025 - $0.88 |
| Next EPS Report Date: 02/03/26 |
|
|
|
| |
